Skip to main content
Retour
PTCT logo

PTC Therapeutics, Inc.

Qualité des données : 100%
PTCT
NASDAQ Healthcare Biotechnology
66,42 €
▲ 1,12 € (1,72%)
Cap. Boursière : 5,50B
Fourchette du Jour
65,94 € 69,02 €
Fourchette 52 Semaines
35,95 € 87,50 €
Volume
827 329
Moyenne 50J / 200J
70,95 € / 63,75 €
Clôture Précédente
65,30 €

Historique des Prix

Tendances Financières

Comparaison Sectorielle

vs médiane du secteur Healthcare (626 pairs)

Métrique Action Médiane du Secteur
P/E 8,1 0,4
P/B 2,9
ROE % 3,8
Net Margin % 39,4 3,9
Rev Growth 5Y % 33,9 10,0
D/E 0,2

Objectif de Cours des Analystes

Hold
84,50 € +27.2%
Low: 50,00 € High: 120,00 €
BPA Prévisionnel
-0,69 €
CA Est.
960 M

Estimations de Bénéfices

Période BPA Est. CA Est. Analystes
FY2030 4,88 €
3,53 € – 6,30 €
1,7 B 2
FY2029 4,12 €
2,98 € – 5,32 €
1,6 B 4
FY2028 1,47 €
-3,92 € – 8,37 €
1,4 B 6

Points Clés

Revenue grew 33,89% annually over 5 years — strong growth
Net margin of 39,44% shows strong profitability
Generating 702,34M in free cash flow
P/E of 8,05 — trading at a low valuation
Revenue growth is accelerating — 1Y growth exceeds 5Y average by 80,62%
Cash machine — converts 102,88% of earnings into free cash flow

Croissance

Revenue Growth (5Y)
33,89%
Revenue (1Y)114,51%
Earnings (1Y)N/A
FCF Growth (3Y)N/A

Qualité

Return on Equity
N/A
ROIC223,85%
Net Margin39,44%
Op. Margin49,49%

Sécurité

Debt / Equity
N/A
Current Ratio2,35
Interest Coverage5,63

Valorisation

P/E Ratio
8,05
P/B RatioN/A
EV/EBITDA5,84
Dividend Yield0,00%

All Fundamental Metrics

Growth
Revenue Growth (1Y) 114,51% Revenue Growth (3Y) 35,85%
Earnings Growth (1Y) N/A Earnings Growth (3Y) N/A
Revenue Growth (5Y) 33,89% Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) 1,73B Net Income (TTM) 682,64M
ROE N/A ROA 23,45%
Gross Margin 95,85% Operating Margin 49,49%
Net Margin 39,44% Free Cash Flow (TTM) 702,34M
ROIC 223,85% FCF Growth (3Y) N/A
Safety
Debt / Equity N/A Current Ratio 2,35
Interest Coverage 5,63 Dividend Yield 0,00%
Valuation
P/E Ratio 8,05 P/B Ratio N/A
P/S Ratio 3,18 PEG Ratio -0,03
EV/EBITDA 5,84 Dividend Yield 0,00%
Market Cap 5,50B Enterprise Value 5,01B

Income Statement

Annual, most recent first

Income statement data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue 1,73B 806,78M 937,82M 698,80M 538,59M
Net Income 682,64M -363,30M -626,60M -559,02M -523,90M
EPS (Diluted) 7,78 -4,73 -8,37 -7,79 -7,43
Gross Profit 1,66B 749,38M 872,34M 654,12M 506,27M
Operating Income 856,51M -302,57M -439,50M -447,41M -374,44M

Balance Sheet

Annual, most recent first

Balance sheet data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 2,91B 1,71B 1,90B 1,71B 1,94B
Total Liabilities 3,12B 2,80B 2,71B 2,05B 1,94B
Shareholders' Equity -205,31M -1,10B -818,56M -347,09M 1,44M
Total Debt 492,28M 2,47B 2,23B 1,46B 1,27B
Cash & Equivalents 984,65M 779,71M 594,00M 279,83M 189,72M
Current Assets 2,27B 1,37B 1,22B 693,79M 954,37M
Current Liabilities 968,43M 580,98M 603,10M 406,24M 509,35M